Медико-биологический
информационный портал
для специалистов
 
Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г.  2020 г.  2021 г.  2022 г.  2023 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 23, Art. 31 (pp. 556-572)    |    2022       
»

Historical aspects of the study and practical application of plant toxins ricin and abrin
Nikishin A.S., Myasnikov V.A., Ilinskiy N.S., Pugach V.A.

State Scientific Research Testing Institute of Military Medicine of the Ministry of Defense of Russia



Brief summary

The paper presents the historical aspects of the study and practical application of lectins of plant origin, ricin and abrin. The two most actual vectors of their consideration today are reflected. One of them concerns the issues of development of effective antitumor agents based on toxins and the other one is about potential threat of use the toxins as biological damaging agents. The discussion of the first direction includes a demonstration of the main achievements and existing problems that limit the introduction of the drugs into clinical practice. The second one involves generalization of facts that arguing the preservation of a high probability of using ricin and/or abrin as a means of bioterrorism and the need to improve countermeasures in this regard


Key words

ricin, abrin, study history, biological damaging agents, antitumor agents.





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Walsh M. J., Dodd J. E., Hautbergue G. M. Ribosome-inactivating proteins: potent poisons and molecular tools. Virulence. 2013; 4 (8): 774-784.


2. Olsnes S. The history of ricin, abrin and related toxin. Toxicons. 2004; 44 (4): 361-370.


3. Patocka J. Abrin and ricin-two dangerous poisonous proteins. ResearchGate. 2002. Available at: https://www.researchgate.net/publication/285477944 (data obrasheniya: 15.11.2021).


4. Roxas-Duncan V. I. Of beans and beads: ricin and abrin in bioterrorism and biocrime.


J. Bioterr. Biodef. 2011: 2156-2164.


5. Facts about abrin. Center for disease control and prevention. Available at: https://emergency.cdc.gov/agent/abrin/basics/facts.asp (data obrasheniya: 15.11.2021).


6. Franke H., Scholl R., Aigner A. Ricin and Ricinus communis in pharmacology and toxicology - from ancient use and "Papyrus Ebers" to modern perspectives and "poisonous plant of the year 2018". Arch. Pharm. 2019; 392 (10): 1181-1208.


7. Bolognesi M., Bortolotti M., Maiello S., Battelli M. G., Polito L. Molecule?s ribosome-inactivating proteins from plants: a historical overview. Molecules. 2016; 21 (12): 1627-1639.


8. O'Hara J. M., Yermakova A., Mantis N. J. Immunity to ricin: fundamental insights into toxin-antibody interactions. Curr. Top. Microbiol. Immunol. 2012: 209-241.


9. Tyagi N., Tyagi M., Pachauri M., Ghosh P. C. Potential therapeutic applications of plant toxin-ricin in cancer: challenges and advances. Tumour Biol. 2015; 36 (11): 8239-8246.


10. Barceloux D. G. Medical toxicology of natural substances: foods, fungi, medicinal herbs, plants, and venomous animals. Springer; 2008: 1155 p.


11. Antonov N. S. Himicheskoe oryjie na rybeje dvyh stoletii. M.: Progress; 1994: 173 s.


12. Griffiths G. D. Understanding ricin from a defensive viewpoint. Toxins (Basel). 2011; 3 (11): 1373-1392.


13. Gaillard Y., Regenstreif P., Fanton L. Modern toxic antipersonnel projectiles. Am. J. Forensic. Med. Pathol. 2014; 35 (4): 258-264.


14. Gopalakrishnakone P., Balali-Mood M., Llewellyn L. Biological toxins and bioterrorism. Springer. Netherlands; 2015: 611 p.


15. Miteva O. A., Bikova K. A., Myasnikova I. A., Chepyr S. V., Al-Shehadat R. I. Analiz sovremennih metodov i sredstv ekspressnoi indikacii rastitelnih toksinov, ingibiryushih sintez belka. Medline.ru. 2020; 21: 579-592.


16. Audi J., Belson M., Patel M., Schier J., Osterloh J. Ricin poisoning: a comprehensive review. JAMA. 2005; 294 (18): 2342-2351. doi: 10.1001/jama.294.18.2342.


17. Vance D. J., Mantis N. J. Progress and challenges associated with the development of ricin toxin subunit vaccines. Expert. Rev. Vaccines. 2016; 15 (9): 1213-1222. doi: 10.1586/14760584.2016.1168701.


18. Pincus S. H., Smallshaw J. E., Song K., Berry J., Vitetta E. S. Passive and active vaccination strategies to prevent ricin poisoning. Toxins (Basel). 2011; 3 (9): 1163-1184.


19. Pratt T. S., Pincus S. H., Hale M. L., Moreira A. L., Roy C. J., K.-M. Tchou-Wong Oropharyngeal aspiration of ricin as a lung challenge model for evaluation of the therapeutic index of antibodies against ricin A-chain for post-exposure treatment. Exp. Lung. Res. 2007; 33: 459-481.


20. Gal Y., Mazor O., Alcalay R., Seliger N., Aftalion M., Sapoznikov A. et. al. Antibody/doxycycline combined therapy for pulmonary ricinosis: attenuation of inflammation improves survival of ricin-intoxicated mice. Toxicol. Rep. 2014; 1: 496-504.


21. Falach R., Sapoznikov A., Alcalay R., Aftalion M., Ehrlich S., Makovitzki A. et. al. Generation of highly efficient equine-derived antibodies for post-exposure treatment of ricin intoxications by vaccination with monomerized ricin. Toxins. 2018; 10 (11): 466-479.


22. Whitfield S., Griffiths G. D., Jenner D. C., Gwyther R. J., Stahl F. M., Cork L. J. et. al. Production, characterisation and testing of an ovine antitoxin against ricin; efficacy, potency and mechanisms of action. Toxins. 2017; 9 (10): 329-340.


23. Dong N., Luo L., Wu J., Jia P., Li Q., Wang Y. Monoclonal antibody, mAb 4C13, an effective detoxicant antibody against ricin poisoning. Vaccine. 2015; 33 (32): 3836-3842.


24. Respaud R., Marchand D., Pelat T., Tchou-Wong K.-M., Roy C. J., Parent C. et al. Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin. J. Control Release. 2016: 21-32.


25. O?Hara J. M., Whaley K., Pauly M., Zeitlin L., Mantis N. J. Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit. Vaccine. 2012; 30 (7): 1239-1243.


26. Hu W., Yin J., Chau D., Negrych L. M., Cherwonogrodzky J. W. Humanization and characterization of an anti-ricin neutralization monoclonal antibody. PLoS One. 2012; 7 (9): 456-466.


27. Roy C. J., Ehrbar D. J., Bohorova N., Bohorov O., Kim D., Pauly M. Rescue of rhesus macaques from the lethality of aerosolized ricin toxin. JCI Insight. 2019; 4 (1): 456-464.


28. Noy-Porat T., Rosenfeld R., Ariel N., Epstein E., Alcalay R., Zvi A. et. al. Isolation of anti-ricin protective antibodies exhibiting high affinity from immunized non-human primates. Toxins. 2016; 8 (3): 64-78.


29. Noy-Porata T., Alcalaya R., Epstein E., Sabo T., Kronman C., Mazor O. Extended therapeutic window for post-exposure treatment of ricin intoxication conferred by the use of high-affinity antibodies. Toxicon. 2017; 27: 100-105.


30. Das A., Jain V., Mishra A. A brief review on a traditional herb: abrus precatorius (L.). IP. Int. J. Forensic. Med. Toxicol. Sci. 2016; 1 (1): 1-10.


31. Abrin - Another Poison Being Experimented with by Terrorists. Food safty magazine Available at: https//www.food-safety.com/articles/6437-abrin-another-poison-being-experimented-with-by-terrorists (data obrasheniya: 01.12.2021).


32. Wang J., Gao S., Xin W. A novel recombinant vaccine protecting mice against abrin intoxication. Hum. Vaccin. Immunother. 2015; 11 (6): 1361-1367. doi: 10.1080/21645515.2015.1008879.


33. Han Y.-H., Gao S., Xin W.-W., Kang L., Wang J.-L. A recombinant mutant abrin A chain expressed in Escherichia coli can be used as an effective vaccine candidate. Hum. Vaccin. 2011; 7 (8): 838-844. doi: 10.4161/hv.7.8.16258.


34. Sabo T., Gal Y., Elhanany E. Antibody treatment against pulmonary exposure to abrin confers significantly higher levels of protection than treatment against ricin intoxication. Toxicol. Lett. 2015; 237 (2): 72-78.


35. Mechaly A., Alcalay R., Noy-Porat T. Novel phage display-derived anti-abrin antibodies confer post-exposure protection against abrin intoxication. Toxins (Basel). 2018; 10 (2): 82-90.


36. Surendranath K., Karande A. A. A neutralizing antibody to the a chain of abrin inhibits abrin toxicity both in vitro and in vivo. Clin. Vaccine. Immunol. 2008; 15 (5): 737-743.


37. Polito L., Bortolotti M., Battelli M. G., Calafato G., Bolognesi A. Ricin: An ancient story for a timeless plant toxin. Toxins (Basel). 2019; 11 (6): 324-331.


38. Lin J. Y., Chen C. C., Lin L. T., Tung T. C. Inhibitory effect of abrin on Ehrlich ascites tumor. Taiwan. 1969; 68 (10): 522-525.


39. Gundersen S., Fodstad O. Treatment of micrometastases from Lewis lung carcinoma with abrin and cyclophosphamide, given singly and in combination. Int. J. Cancer. 1979; 23 (4): 530-535.


40. Fodstad O., Pihl A. Effect of ricin and abrin on survival of L1210 leukemic mice and on leukemic and normal bone-marrow cells. Int. J. Cancer. 1978; 22 (5): 558-563.


41. Fodstad O., Kvalheim G., Godal A., Lotsberg J., Aamdal S., Høst H. A Pihl Phase I study of the plant protein ricin. Cancer Res. 1984; 44 (2): 862-865.


42. Shapira A., Benhar I. Toxin-based therapeutic approaches. Toxins (Basel). 2010; 2 (11): 2519-2583.


43. Byers V. S., Rodvien R., Grant K., Durrant L. G., Hudson K. H., Baldwin R. W. et. al. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res. 1989; 49 (21): 6153-6160.


44. Weiner L. M., O'Dwyer J., Kitson J., Comis R. L., Frankel A. E., Bauer R. J. et. al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 1989; 49 (14): 4062-4067.


45. Chavez-Cortez E.-G., Felix G. V., López E. R., Sotelo J., Martínez-Canseco C., Pérez-de la Cruz V. et al. Production and evaluation of an avian IgY immunotoxin against CD133+ for treatment of carcinogenic stem cells in malignant glioma: IgY immunotoxin for the treatment of glioblastoma. J. Oncol. 2019. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582814 (data obrasheniya: 20.11.2021).


46. Loan N. T. B. Anticancer activities of ricin-liposome complexes on SKMEL-28. Cel. Asian Pac. J. Cancer Prev. 2019; 20 (7): 2117-2123.





Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100